J Bund1, K Eberhardt, W Hartmann, H J Habermalz. 1. Radiologische Klinik, Medizinischer Bereich Strahlentherapie, Zentralkrankenhauses Sankt-Jürgen-Strasse Bremen.
Abstract
BACKGROUND: In-vitro and in-vivo studies demonstrated the radiosensitizing effect of interferon beta on malignant tumor tissue as well as simultaneously a radioprotective effect on normal lung tissue. In this phase II study the outcome of combining radiotherapy with interferon beta in patients with advanced non-small cell lung cancer was evaluated. PATIENTS AND METHOD: From February 1994 until November 1996 14 patients with non-small cell lung cancer, stage IIIB were treated with locoregional radiation up to 59.4 Gy, with daily doses of 1.8 Gy and 5 fractions per week. Five million units of interferon beta (Fiblaferon) were given intravenously immediately preceding radiotherapy on the first 3 days of week 1, 3 and 5. RESULTS: Four of 14 patients (28.6%) showed complete response and 7 patients (50%) partial response, resulting in an overall response rate of 78.6%. After a mean follow-up time of 23.3 months the 1-, 2- and 3-year survival rates were 56.3%, 37.5% and 37.5%, respectively. The median survival time was 13 months. Three of 14 patients (21.4%) suffered from 7 Grade-3 acute side effects and 2 patients (14.3%) from 1 Grade-3 late toxicity in each case. One further patient, whose right lung was resected 3 months after completion of radiotherapy, developed as a consequence of this operation 2 Grade-4 complications. CONCLUSION: Considering the toxicity and the preliminary results of combining irradiation and interferon beta in the treatment of locally advanced non-small cell lung cancer it seems, that this procedure is worth to be tested in a phase III study.
BACKGROUND: In-vitro and in-vivo studies demonstrated the radiosensitizing effect of interferon beta on malignant tumor tissue as well as simultaneously a radioprotective effect on normal lung tissue. In this phase II study the outcome of combining radiotherapy with interferon beta in patients with advanced non-small cell lung cancer was evaluated. PATIENTS AND METHOD: From February 1994 until November 1996 14 patients with non-small cell lung cancer, stage IIIB were treated with locoregional radiation up to 59.4 Gy, with daily doses of 1.8 Gy and 5 fractions per week. Five million units of interferon beta (Fiblaferon) were given intravenously immediately preceding radiotherapy on the first 3 days of week 1, 3 and 5. RESULTS: Four of 14 patients (28.6%) showed complete response and 7 patients (50%) partial response, resulting in an overall response rate of 78.6%. After a mean follow-up time of 23.3 months the 1-, 2- and 3-year survival rates were 56.3%, 37.5% and 37.5%, respectively. The median survival time was 13 months. Three of 14 patients (21.4%) suffered from 7 Grade-3 acute side effects and 2 patients (14.3%) from 1 Grade-3 late toxicity in each case. One further patient, whose right lung was resected 3 months after completion of radiotherapy, developed as a consequence of this operation 2 Grade-4 complications. CONCLUSION: Considering the toxicity and the preliminary results of combining irradiation and interferon beta in the treatment of locally advanced non-small cell lung cancer it seems, that this procedure is worth to be tested in a phase III study.
Authors: C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman Journal: Cancer Date: 1987-06-01 Impact factor: 6.860
Authors: L R Holsti; K Mattson; A Niiranen; C G Standertskiöld-Nordenstam; S Stenman; A Sovijärvi; K Cantell Journal: Int J Radiat Oncol Biol Phys Date: 1987-08 Impact factor: 7.038
Authors: W T Sause; C Scott; S Taylor; D Johnson; R Livingston; R Komaki; B Emami; W J Curran; R W Byhardt; A T Turrisi Journal: J Natl Cancer Inst Date: 1995-02-01 Impact factor: 13.506
Authors: T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; M Tarayre; M J Lacombe-Terrier; J Y Douillard; A Laplanche Journal: J Natl Cancer Inst Date: 1991-03-20 Impact factor: 13.506
Authors: S McDonald; A Y Chang; P Rubin; J Wallenberg; I S Kim; S Sobel; J Smith; P Keng; A Muhs Journal: Int J Radiat Oncol Biol Phys Date: 1993-10-20 Impact factor: 7.038
Authors: M G Trovó; E Minatel; G Franchin; M G Boccieri; O Nascimben; G Bolzicco; G Pizzi; A Torretta; A Veronesi; C Gobitti Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: D R Gandara; F H Valone; E A Perez; A B Deisseroth; M Roach; D K Ahn; T Phillips Journal: Int J Radiat Oncol Biol Phys Date: 1991-05 Impact factor: 7.038